Recent briefings contained no material Eli Lilly-specific corporate disclosures in the period to early July 2026 [Brief - 2026-07-03]. The broader macro backdrop during this period included a US nonfarm payrolls reading of 57,000 for June, materially below consensus estimates of 110,000–115,000, reshaping the Federal Reserve rate debate [Brief - 2026-07-03]. US equity markets recorded their strongest quarterly performance in six years as of 30 June 2026, driven in part by a US Supreme Court ruling that reversed the Trump administration's tariff policies [Brief - 2026-06-30]. The death of Iranian Supreme Leader Ayatollah Ali Khamenei introduced additional geopolitical uncertainty into global markets during the same period [Brief - 2026-07-05].
Eli Lilly's trailing twelve-month revenue stood at $72.25 billion as of 31 March 2026, representing year-over-year growth of 55.5%. Net income for the same period was $25.28 billion, yielding a net margin of approximately 35.0%. Earnings per share grew 169.9% year-over-year on a TTM basis. The company held $5.28 billion in cash against total debt of $43.37 billion. The reported price-to-earnings ratio was 42.22 at the time of the filing [SEC 10-Q - LLY - 2026-03-31].
Four insider transactions were recorded in July 2026, with a mixed directional profile and a net reported value of zero [SEC Form 4 - LLY - 2026-07]. Among institutional holders, Citadel reduced its position by 29% and Millennium Management reduced its position by 6.5% [SEC 13F - Citadel - Q1 2026] [SEC 13F - Millennium - Q1 2026]. Conversely, AQR Capital added 69% to its existing position, and ARK Invest opened a new position in the company during the same reporting period [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - ARK Invest - Q1 2026].
The US 10-year Treasury yield stood at 4.54% and the 2-year yield at 4.16% at the time of this report, producing a normal yield curve configuration with a spread of 38 basis points [FRED DGS10] [FRED DGS2]. These conditions form part of the broader interest rate environment in which large-cap equities with elevated debt loads, such as Eli Lilly's $43.37 billion in total debt, are currently operating [SEC 10-Q - LLY - 2026-03-31]. The material divergence in institutional position changes across multiple prominent filers was the primary trigger for this report.